Lantern Pharma (NASDAQ:LTRN) CEO Panna Sharma joined Steve Darling from Proactive to share news the company has presented preclinical data on the potency of drug candidate LP-284 for mantle cell lymphoma and several other non-Hodgkin’s lymphomas using its RADR technology. Sharma talks more about the results and how LP-284 is the next generation acylfulvene that has a synthetically lethal mechanism of action in cancers with impaired DNA damage repair pathway genes.
Lantern Pharma releases positive Preclinical Data on Efficacy of LP-284 for Mantle Cell Lymphoma
